Curis Inc (NASDAQ:CRIS)

5.12
Delayed Data
As of Nov 26
 +0.04 / +0.79%
Today’s Change
1.09
Today|||52-Week Range
17.40
-37.48%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$467.2M

Company Description

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Contact Information

Curis, Inc.
128 Spring Street
Lexington Massachusetts 02421
P:(617) 503-6500
Investor Relations:

Employees

Shareholders

Other institutional46.03%
Mutual fund holders32.78%
Individual stakeholders0.23%

Top Executives

James E. DentzerPresident, Chief Executive Officer & Director
William E. SteinkraussChief Financial Officer & Treasurer
Mark W. NoelVP-Technology Management & Intellectual Property
Robert E. MartellHead-Research & Development
Reinhard von RoemelingSenior Vice President-Clinical Development